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Abstract
Background: The Blau syndrome (MIM 186580), an autosomal dominant granulomatous disease,
was previously mapped to chromosome 16p12-q21. However, inconsistent physical maps of the
region and consequently an unknown order of microsatellite markers, hampered us from further
refining the genetic locus for the Blau syndrome. To address this problem, we constructed our own
high-resolution physical map for the Blau susceptibility region.
Results: We generated a high-resolution physical map that provides more than 90% coverage of
a refined Blau susceptibility region. The map consists of four contigs of sequence tagged site-based
bacterial artificial chromosomes with a total of 124 bacterial artificial chromosomes, and spans
approximately 7.5 Mbp; however, three gaps still exist in this map with sizes of 425, 530 and 375
kbp, respectively, estimated from radiation hybrid mapping.
Conclusions: Our high-resolution map will assist genetic studies of loci in the interval from
D16S3080, near D16S409, and D16S408 (16q12.1 to 16q13).
Background
High-resolution genetic maps are essential to identifying
and characterizing the gene(s) contributing to diseases,
that is, they are essential for making the transition from
positional cloning to the positional candidate approach.
If the physical order of markers used for linkage analysis
is incorrect, the position of the putative locus may at best
be incorrect and at worst be found not to exist in the true
interval. We were hampered in our efforts to fine map the
gene for the Blau syndrome because we were faced with an
uncertain marker order in maps that had many inconsist-
encies.
The Blau syndrome (MIM 186580), an autosomal domi-
nant granulomatous disease of childhood, is a rare famil-
ial granulomatous disease [1]. Affected individuals
typically display one or more of the following granuloma-
tous inflammations that have variable age-at-onset: acute
anterior uveitis, arthritis, and skin rash. The phenotype of
the Blau syndrome resembles another multisystem granu-
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lomatous disorder, Crohn's disease (MIM 266600), and
another autoimmune disease, psoriasis (MIM 177900).
These three inflammatory diseases not only share pheno-
typic features, but a subset of putative risk loci mapped to
an overlapping region on chromosome 16. Of the several
putative susceptibility loci for Crohn's disease [2–7] and
psoriasis [8], the Crohn's locus on 16q between markers
D16S409 and D16S419 (56.1–65.6 cM from p-terminus)
[5] and the psoriasis locus on 16q near D16S3110 [8]
overlap with the locus for the Blau syndrome. Interesting-
ly, another autoimmune disease ankylosing spondylitis
(MIM 106300), also maps to chromosome 16q, however,
it appears to map telomeric to the Blau syndrome interval
[9,10].
While our studies were in progress, other groups detected
mutations in the CARD15 gene for a subset of Crohn's dis-
ease patients, and in three small Blau syndrome families
[11,12]. The lack of accurate maps is reflected in the posi-
tion assigned to CARD15 in consecutive genome builds in
that CARD15 should map to the 16q13 interval for Blau
and Crohn's, yet in build 27 it was mapped close to the p-
telomere of chromosome 16. In the current build, 29, it is
located correctly (see additional data file 1,
blau_map.pdf). Until the draft human genome is truly
complete, detailed regional physical maps will be indis-
pensable for genetic studies.
We have previously reported that the Blau syndrome sus-
ceptibility region resided between D16S298 and D16S408
[13]. Here we generated a high-resolution map extending
from D16S3080, near D16S409, to D16S408 and placed
four plausible candidate genes (CES1, MMP2, MMP15
and SCYA17) in the map. We also excluded the four can-
didate genes as the genes harbouring mutations causing
the Blau syndrome.
Results
High-resolution RH map
To generate a framework order of markers, we used three
RH panels (Table 1) and the RHMAP program package.
We typed the GeneBridge 4 panel for 54 markers to verify
that they occurred near, or in, the interval between
D16S409 and D16S408. The G3 panel was typed for a to-
tal of 77 markers and the TNG panel for 83 markers. The
markers were clustered into linkage groups by two-point
analyses using RH2PT and a criterion of a lod score greater
than or equal to 4. Multipoint analyses were performed
on linkage groups as well as sparse linkage groups togeth-
er with markers from other linkage groups. Several
multipoint maximum likelihood framework maps were
constructed using the RHMAXLIK program of the RHMAP
package and equal retention probabilities and the branch
ordering scheme options, which gives the highest proba-
bility of finding the correct order [14]. The G3 RH map
(see additional data file 1, blau_map.pdf) provided an or-
der for the construction of the BAC contigs. Although the
TNG panel generated a useful map, there were unresolved
regions where it appeared that the panel did not provide
sufficient data to differentiate between alternative marker
orders. We merged the G3 and TNG data by establishing a
G3 framework map that fixed the order of a subset of
markers. Clusters of close markers containing at least two
G3 mapped markers were then mapped relative to one-
another using the TNG data. By integrating the G3 and the
TNG maps, an overall contiguous RH map of the region
between the markers D16S411 and D16S415 was con-
structed in which the marker order of most loci could be
determined with a likelihood ratio of greater than 300:1
over the next most likely order (data not shown).
BAC contig construction
We carefully selected STSs from within or around the Blau
candidate interval to screen two BAC libraries. More than
130 STSs were chosen from those in known genes, ESTs,
polymorphic microsatellite markers, random genomic se-
quences, and BAC end sequences present in databases.
Construction of a BAC clone contig was initiated by
screening the CITB library with all the STS markers. The
clone contigs were constructed based on the common
BACs identified by two or more markers, using the RH
map described above and the existing framework map re-
sources as reference for ordering.
We initially identified 377 unique CITB clones with one
or more STS hits from which a subset of 41 clones that
contained at least two markers was used to construct 17
contig clusters (see additional data file 1, blau_map.pdf).
These 41 non-redundant CITB clones in the contigs cov-
ered less than 50% of the broad Blau syndrome interval.
The remaining 336 CITB clones were redundant in that
they either were identified by a single marker or were
identified by the same markers as the 41 non-redundant
Table 1: Summary of radiation hybrid panel features.
GeneBridge 4 Stanford 
G3
Stanford 
TNG
Resolution Low Medium High
No. hybrids 93 83 90
Fraction of genome per hybrid 0.32 0.18 0.16
Average fragment size 10 Mbp 4 Mbp 800 kbp
X-ray dosage (cR) 3,000 10,000 50,000
Units cR3000 cR10000 cR50000
kbp per unit 270 25 4
Average resolution 1000 kbp 267 kbp 60 kbpBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/24
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clones. Gaps in the contigs were closed by a combination
of DNA sequence alignments of BESs with HTGS data,
clone walking using RNA probes from end clones to hy-
bridize to the RPCI-11 gridded filters, and verification of
clone positions by PCR for STSs. From the BAC contigs,
eight clones from both ends of the contig clusters were se-
lected for sequencing using T7 and SP6 primers. Sequence
alignments with these 16 end sequences revealed that two
sequences, CITB_361N2-T7 and CITB_520M7-SP6, iden-
tified one common clone from the online HTGS, which
was RPCI-11_147B17 (Figure 1).
BES alignment was a very feasible and practical technique
for filling in the gaps with the availability of an ever-in-
creasing number of BAC clone sequences in online data-
bases. Using this approach, one gap between marker
D16S2986 and Cda11d08 was closed. STS marker
D16S2986 was initially used to search the HTGS data and
one clone RPCI-11_357N13 was retrieved with 100%
identity. BES from clone 357N13 was then used to repeat
the alignment searches and identified another clone
RPCI-11_488J11, which overlapped STS markers
Cda11d08 and WI-16741.
Two rounds of clone walking were carried out in order to
either close the gaps or verify the order of the clone con-
tigs. All the plasmid DNAs from these clones were isolated
and completely digested by Hind III into linear fragments
for run-off transcription. Since RNA probes were directly
transcribed from human genomic sequence, it was neces-
sary to test the probes for repetitive sequences. The pres-
ence of repetitive sequences can hinder the specific
identification of BAC clones from the library filters. Of 44
probes tested, three probes produced multiple bands with
the genomic DNA indicating that they contained repeti-
tive sequences, and were, therefore, excluded from further
analyses. We identified more than 400 clones from the
RPCI-11 library of which 83 were incorporated (see addi-
Figure 1
Schema illustrating the use of BES alignment to close one of the 16 gaps in the early version of our map. T7 and
SP6 in solid arrows indicate sequences derived from the T7 and SP6 promoters, respectively, of BAC clones. Dashed arrows
indicate matches with sequences from the corresponding clone in the databases. Boxes represent clones and STS markers are
indicated at top. An approximate distance derived from the G3 RH map is shown.
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tional data file 1, blau_map.pdf). After one round of clone
walking, the physical map covered more than 80% of the
broad Blau syndrome interval. A second round increased
coverage to greater than 90%. Three unresolved gaps re-
main in the physical map (see additional data file 1,
blau_map.pdf).
Comparison of BAC contig to other maps
We compared our map to the current, July 1, 2002, contigs
generated by fingerprinting and available from the FPC
database at Washington University Genome Sequencing
Center. The FPC database has few clones from the CITB li-
brary and none that corresponded to the clones on our
map (see additional data file 1, blau_map.pdf).
Of 83 RPCI-11 clones in our contigs, 63 were present in
the FPC database; 1 was not placed on a contig, 6 were
placed on contigs of different chromosomes, and 56 in
three chromosome 16 contigs, ctg16020, ctg16021 and
ctg16024. The gap between ctg16020 and ctg16021 corre-
sponds to gap 1 (see additional data file 1,
blau_map.pdf). FPC contig ctg16020 is oriented q-tel-
omere to centromere, i.e. reversed with respect to our
map. One clone, 420D3 was placed in ctg16020, however,
our data suggest it should be in ctg16020 close to 122K22
and 444I18. Our data also reversed the order of clones
380E14, 210K18 and 535L14 in ctg16020. Aside from
one minor difference with respect to clone 444I18 that
our data place slightly closer to the q telomere, the re-
maining 37 clones of contig ctg16021 that were common
to both maps agreed very well. There was a single clone in
ctg16024, 463J22 that our data place in ctg16021, near
228I15. Interestingly, one of the clones, 327F22, that was
placed on a contig from a different chromosome was the
clone that contains all or part of CARD15.
The NCBI build current at the time our map was being fi-
nalized was build 25 (see additional data file 1,
blau_map.pdf). There were a large number of discrepan-
cies between our map and the build 25 map. The gene
subsequently characterized as having mutations in Blau
syndrome families was not in the interval. The discrepan-
cies largely remained until builds 28 and 29. Build 29, the
current build, of NCBI agrees very well with our map (see
additional data file 1, blau_map.pdf).
Candidate genes
Four genes, CES1, MMP2, MMP15 and SCYA17, with rel-
evant biochemical functions based on the literature and
with map locations in the broad Blau susceptibility region
as defined by our initial DNA linkage study for the Blau
syndrome [13], were considered as candidates. CES1 is ex-
pressed in mature monocytes and macrophages, and is in-
volved in the degradation of xenobiotics [15]. MMP2 or
MMP15, or both, are connective tissue degrading enzymes
[16]. A hypothetical role for MMP2 and MMP15 in the
Blau syndrome is that aberrant expression of MMP2 and
MMP15 could inappropriately degrade connective tissue,
which, in turn, could release stored cytokines and inflam-
matory mediators, such as tumor necrosis factor α  and in-
terleukins and potentially expose neo-epitopes. SCYA17 is
a member of the CC group of chemokines that is involved
in immunoregulatory and inflammatory processes [17–
19]. It is a chemoattractant for T lymphocytes and is ex-
pressed constitutively in thymus and transiently in stimu-
lated peripheral blood monocytes [20]. Interestingly, high
levels of expression of SCYA17 were observed in lipopol-
ysaccharide-stimulated human monocytes [21]. Sekiya et
al. [22] showed that SCYA17 potentially played a role via
a paracrine mechanism in the development of allergic res-
piratory diseases. Thus, inappropriate topical expression
of SCYA17 could induce a localized immune or auto-im-
mune response.
A total of 13 sequence variants were identified in the pro-
moter region of the CES1 gene (Table 2) by sequencing 33
members from the Blau families. Seven thirteen-marker
haplotypes could be assigned unambiguously (Table 3)
using extended pedigree structures (data not shown),
however, none of them was associated with the Blau syn-
drome phenotype. The CES1 gene was, therefore, exclud-
ed as a candidate for the Blau syndrome.
RH mapping of CES1 and MMP2 placed them close, and
centromeric, to D16S408 (see additional data file 1,
blau_map.pdf), whereas MMP15 and SCYA17 mapped te-
lomeric to D16S408. The MMP15 locus was placed be-
tween D16S408 and D16S494 using the GeneBridge 4 RH
panel. CES1 and MMP2 were mapped to clones in the
BAC contigs (see additional data file 1, blau_map.pdf),
whereas SCYA17 and the markers Cda1jb12 and R55777
were mapped to the BAC clones, CITB_387I12,
CITB_437K19 and CITB_229H3, which map 1.1 Mbp tel-
omeric to D16S408 according to the NCBI human ge-
nomic data (data not shown). Our own RH distance
estimates also place these markers more than 1 Mbp telo-
meric to D16S408. In our G3 RH map CES1 was located
outside a subsequently refined Blau syndrome interval
that excluded several cM centromeric to D16S408, thus
confirming the lack of association between CES1 haplo-
types and the disease phenotype.
Mutations were characterized in the gene CARD15 for a
few small families with the Blau syndrome [11,12]. We
have characterized additional mutations in Blau syn-
drome families, however, only five of ten families had
mutations in the exons and flanking sequences (X. Wang,
H. Kuivaniemi, G. Bonavita, L. Mutkus, U. Mau, E. Blau,
N. Inohara, G. Nunez, G. Tromp and C.J. Williams; in
press). The gene was located in the approximate intervalBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/24
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both cytologically and on the Santa Cruz map  [http://ge-
nome.ucsc.edu/cgi-bin/hgGateway?db=hg10], but was lo-
cated on chromosome 16p on the NCBI map (builds 25
to 28). We verified the location of CARD15 on our map
by amplifying a 444 bp fragment of exon 4 from clone
327F22 in our map (see additional data file 1,
blau_map.pdf).
Discussion
Correct marker order and intermarker distance are essen-
tial for linkage analysis and therefore require construction
of accurate physical and genetic maps. Here we employed
BAC contig and RH mapping to construct a high-resolu-
tion physical map, which spans approximately 7.5 Mbp of
chromosome 16 between markers D16S3080 and
D16S408. This map will definitely assist in the refinement
Table 2: Summary of the sequence variants in the promoter region of the CES1 gene.
Genotypes at locations
Sample Gender Pheno-
type
939 968 975 993 994 1012 1024 1028 1029 1032 1047 1081 1087
Blau-01 F U G/T G/G G/G C/C G/G G/G C/C T/T C/C G/G G/G G/G T/T
Blau-02 F A G/G G/G G/G C/C G/G G/G C/C T/T C/C G/G G/G G/G T/T
Blau-03 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-04 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A A/A
Blau-05 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-06 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-07 M A T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A A/A
Blau-08 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-09 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-10 F A T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-23 F U G/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-24 M U G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/T
Blau-25 M U G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/T
Blau-26 M A G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Blau-27 F A G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Blau-28 F U G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Blau-29 M A G/G G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Blau-30 M U G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Blau-31 M A G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/T
Blau-11 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-12 F A T/T G/A G/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-13 F U T/T G/A G/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-14 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-33 M A T/T G/G G/G G/C G/A G/C G/C T/C T/C G/A G/T G/A T/T
Blau-15 F A G/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-16 M A G/T A/A G/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-17 F A T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-18 F U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-19 F A T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-20 M U T/T A/A A/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/T
Blau-21 M A G/T A/A G/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-22 M U G/T A/A G/A G/G A/A C/C G/G C/C T/T A/A T/T A/A T/A
Blau-32 M A G/T G/A G/A G/C G/A G/C G/C T/C T/C G/A G/T G/A T/A
Genotypes were derived from five different families, members of one family are separated from those of other families by blank lines.BMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/24
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of the Blau syndrome locus as well as other loci mapping
to this region, such as Crohn's disease [5], psoriasis [8]
and possibly ankylosing spondylitis [9,10].
We constructed a high-resolution RH map (likelihood ra-
tio of greater than 300:1 over the next likely order) with
the medium-resolution G3 and high-resolution TNG
whole-genome RH panels (Figure 1). This map allowed
ordering of the polymorphic markers and estimation of
the distances between them. The marker order provided
the basis for construction of the BAC contig. The inter-
marker distances estimated from RH data were substanti-
ated by the BAC contig data when the average length of
the BAC inserts was used to estimate intermarker distanc-
es. Our BAC contig provides more than 90% coverage of
the entire Blau susceptibility region. The STS-based high-
resolution physical contig consists of 124 BACs, and
spans approximately 7.5 Mb as estimated from the
number of BACs in the shortest tiling path and the average
insert length of the BACs. We have used our map to refine
the Blau syndrome interval (X. Wang, H. Kuivaniemi, G.
Bonavita, L. Mutkus, U. Mau, E. Blau, N. Inohara, G. Nun-
ez, G. Tromp and C.J. Williams; in press).
Another BAC contig map of chromosome 16q constructed
by two-dimensional overlapping oligonucleotide (over-
go) hybridization on high-density BAC filters has been
published [23]. This map consists of 828 overgo markers
and 3,363 BACs providing > 85% coverage of the long
arm of chromosome 16. This contig map, however, does
not cover the entire Blau syndrome region; it ends at the
site of marker D16S2758 in our physical contig (see addi-
tional data file 1). The order for most of the markers is the
same on the two independently generated maps. Never-
theless, there are a few differences. For example, Han et al.
[23] mapped the marker D16S2950 in the order of
D16S2623, D16S2950 and D16S744, with the markers
equidistant at approximately 130 kbp. We found the or-
der to be D16S2623, D16S744 and D16S2950 with inter-
val of approximately 130 kbp and 500 kbp, respectively.
Also, the Han et al. [23] map has six regions in the Blau
susceptibility interval which are either spanned with ten-
uous support or none at all. Two are real gaps with no
overlapping clones and the other four are spanned by few
clones that have either unusually long inserts or are miss-
ing some of the markers in the interval, or both.
Our contig also contains three gaps that we were unable
to close by clone walking. One of them corresponds to
one of the six gaps in the Han et al. [23] map. The other
two are located in the region between markers D16S2758
and D16S408, which is not covered by Han et al. [23]. The
common gap in both physical contigs indicates either a
lack of STS markers in this region or an under-representa-
tion of clones even though two libraries were used in our
study, or both. We estimate from RH data that the three
gaps are only 425, 530, and 375 kbp in size and will not
substantially affect DNA linkage analyses. The first gap
(see additional data file 1), is also present in the FPC con-
tigs, between ctg16020 and ctg16021, whereas the other
two have been filled in.
Conclusions
We generated a high-resolution physical map from
D16S3080, near D16S409, and D16S408 (16q12.1 to
16q13) because the correct marker order was required for
further linkage studies with Blau syndrome families. A
physical map was also necessary to locate, or verify the lo-
cation of, candidate genes. Although there were substan-
tial discrepancies as to the location of markers and genes
at the time we initiated our mapping project, and even
when this physical map was assembled into a final draft,
the current NCBI map based on build 29, the FPC contigs,
and the map produced here, agree remarkably well. The
convergence of three independently constructed maps
based on different approaches, suggests that the current
maps are reliable, will perhaps undergo minor changes,
and will be useful for mapping of disease loci to the inter-
val.
Materials and Methods
PCR of STS markers
Primer pairs for most of the STS markers were purchased
from Research Genetics, and some primers were synthe-
sized by Integrated DNA Technologies, Inc. All test PCRs
were carried out using 30 ng of template DNA with 1.5 µl
GeneAmp 10 ×  PCR buffer II (Roche Molecular Systems,
Inc.), either 1.5 mM or 3.0 mM Mg2+, 200 µM dNTPs, 0.2
Table 3: Different haplotypes constructed from the sequence var-
iants in the CES1 promoter region.
Sequence 
variant site
Haplotype
1234567
9 3 9 GTGTTGT
968 G G A A A A G
9 7 5 GGAAAGG
9 9 3 CCGGGGG
9 9 4 GGAAAAA
1012 G G C C C C C
1024 C C G G G G G
1028 T T C C C C C
1029 C C T T T T T
1032 G G A A A A A
1047 G G T T T T T
1081 G G A A A A A
1087 T T A T A A TBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/24
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µM each forward and reverse primer, and 0.375 units of
AmpliTaq Gold Polymerase (Roche Molecular Systems,
Inc.) in a 15 µl final volume. PCRs were performed in a
model 9600 Thermocycler (Perkin-Elmer Cetus) using the
following cycling protocol: initial denaturation at 94°C
for 10 min; 94.5°C for 1 min, 55–60°C for 1 min, 72°C for
40 s for 35 cycles; followed by a final extension at 72°C for
3 min. PCR products were analyzed on 2% agarose gels.
Genotyping with polymorphic di-, tri-, or tetranucleotide-
repeat markers was performed by PCR according to the
conditions used in the test PCRs above except that one of
the primers was 32P-labeled with T4 polynucleotide ki-
nase. Products were separated on 7% denaturing polyacr-
ylamide gels with or without 50% formamide (Sequagel-
6 or Accugel 19:1; National Diagnostics).
Construction of a RH map
The Whitehead Institute GeneBridge 4, and Stanford G3
and TNG whole genome RH panels (Research Genetics)
were used to construct a RH map. Before typing the hybrid
panels, the PCR conditions for STS markers were deter-
mined using hamster and human genomic DNA as con-
trol templates. PCR products were separated on agarose
gels. PCRs with a band of appropriate size were consid-
ered positive and scored as 1, negative PCRs as 0 and am-
biguous PCRs with bands of unexpected size as 2. The
GeneBridge 4 RH map was constructed using a publicly
available server at the Whitehead Institute at the Massa-
chusetts Institute of Technology. The G3 and TNG maps
were generated using the RHMAP 3.0 program package
[14]. The RH2PT program was used initially to determine
two-point lod scores and all the markers were divided into
different linkage groups. Markers in different linkage
groups were used to carry out maximum likelihood calcu-
lations to estimate breakage probabilities and distances
between markers using another program RHMAXLIK. We
established a G3 framework map of a subset of approxi-
mately evenly spaced markers. Additional markers were
mapped in overlapping sets with G3 panel data until the
likelihood ratio dropped below threshold. Clusters of
closely spaced markers around framework markers were
then mapped using the TNG data and RHMAXLIK. Map
orders were verified by performing independent estima-
tions of likelihood but including markers from adjacent
clusters.
Screening of BAC libraries
A BAC library, CITB, which was generated at the Califor-
nia Institute of Technology in the form of DNA pools ar-
ranged in microtiter plates, was purchased (Research
Genetics). This library offers approximately six-fold cover-
age of the whole genome with an average insert size of 130
kbp. The library is comprised of 147,456 distinct recom-
binants. For rapid screening, DNAs from the clones had
been pooled into 48 superpools, each representing eight
384-well plates that were pooled into eight plate pools, 16
row pools, and 24 column pools. PCR-based screening
consisted of identifying positive superpools followed by
screening of the appropriate plate, row and column pools.
Typically, the three-dimensional screening identified one
or more unique BAC clones from the 3,072 BAC clones in
a superpool. Occasionally, multiple positives in a single
plate (plate, row, column) resulted in non-unique posi-
tives (these also generated false-positives). PCRs were per-
formed as described above except that 1 µl of pooled BAC
library DNA was used as template and the annealing tem-
perature for most markers was raised to 60°C to achieve
greater specificity.
High-density filters of the Roswell Park Cancer Institute
human RPCI-11 BAC clones were purchased from
BACPAC Resource Center at the Children's Hospital Oak-
land Research Institute in Oakland, CA. Segments 1 and 2
of RPCI-11, with a total of 218,995 colonies correspond-
ing to approximately twelve-fold genomic coverage, were
used. The filters were screened iteratively by hybridization
with pools of RNA probes prepared from the ends of BAC
clones identified either by PCR-screening or prior rounds
of hybridization. Hybridizations were performed using
ULTRAhyb buffer (Ambion) and components of the Strip-
EZ RNA kit (Ambion).
Prior to pooling, the probes were tested individually for
the presence of repetitive elements by Southern hybridiza-
tion to the parent BAC DNA and complete Hind III digests
of human DNA. Probes that demonstrated a pattern con-
sistent with the presence of repetitive elements were ex-
cluded.
Field-inversion gel electrophoresis (FIGE)
To determine the size of important BAC inserts, 2 µg of
BAC DNA was first digested with 10 units of Not I (New
England Biolabs). DNA fragments were then separated on
1% pulsed field certified agarose gel (Bio-Rad) in 0.5 ×
GTBE buffer (0.5 ×  TBE, 0.1 M glycine) by FIGE with a PC
750 Pulse Controller (Hoefer Scientific Instruments). The
samples were prerun at 12°C and 8 V/cm for 1 h, and then
run continuously for 17 h with forward pulse 1.2 s, reverse
pulse 0.4 s and timing ramp 0.8/h. A Low-Range PFG
Marker (0.13–194 kbp) (New England Biolabs) was used
for estimation of BAC insert sizes. After electrophoresis,
the gel was stained with ethidium bromide, visualized,
and photographed with a GelPrint2000i system (BioPho-
tonics).
Verification of positive BAC clones
Screening for BAC clones, either by PCR of pooled DNA,
or by hybridisation, produced a wide range of signal in-
tensities. Although differences in signal intensity may beBMC Genomics 2002, 3 http://www.biomedcentral.com/1471-2164/3/24
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considered as a measure of the evidence for the clones' po-
sitions in the contig, the variability of input target DNA
made the conclusions unreliable. Positive clones were
therefore rescreened by PCR with STS markers in the vicin-
ity to eliminate false positive.
Positive clones were purchased from Research Genetics
and colony-blot filters were prepared using a Biomek
1000 Automated Laboratory Workstation with a 96-pin
replicator (Beckman Coulter). The gridded colony-blots
were screened with individual RNA probes from the pools
above. All positive clones were confirmed by PCR with ap-
propriate primer pairs.
Preparation of RNA probes from the ends of BAC clones
BAC DNAs from standard alkaline lysis preparations [24]
were completely digested with Hind III. RNA probes were
synthesized from the ends of clones by run-off transcrip-
tion using the Strip-EZ RNA kit (Ambion) and 32P-UTP
(ICN Radiochemicals). Unincorporated nucleotides were
removed by size-exclusion chromatography on RNase-
free Sephadex G-50 (Sigma) spin columns.
Candidate genes
Four genes, namely, CES1, MMP2, MMP15, and SCYA17,
were selected based on their biochemical function and
physical map locations prior to completion of our high-
resolution map. DNA sequences for the four genes were
obtained from GenBank (accession numbers for CES1:
D21077; MMP2: U96098; MMP15: Z48482; SCYA17:
AC004382). Primers to be used in PCR for each gene were
designed using the Wisconsin Package Version 10.0 (Ge-
netics Computer Group) and synthesized by Operon
Technologies, Inc. PCR conditions other than annealing
temperature used were the same as described above.
The physical locations of the four genes studied were ver-
ified by using RH panels as described below. Their loca-
tions were further refined by screening a BAC library, as
discussed below, using gene-specific PCR primers.
MMP15 and SCYA17 were located telomeric to D16S408
and thus outside the Blau syndrome interval and were ex-
cluded from further studies. MMP2 was placed outside of
a refined Blau syndrome interval that excluded several cM
centromeric from D16S408.
A 755 bp region, nucleotide position -660 to +95, of the
CES1 gene was amplified by PCR from 33 members from
five families with the Blau syndrome. PCR products were
purified (GENECLEAN III, BIO 101 Inc.) to remove prim-
ers and other reagents, and sequenced (Thermo Seque-
nase®, Amersham Life Science, Inc.). Haplotypes were
derived from the inheritance of the variants in the families
(families not shown). Sequencing products were separat-
ed on 7% glycerol-tolerant polyacrylamide sequencing
gels (National Diagnostics).
To verify that the gene for CARD15 is located in the con-
tig, a 444 bp genomic region, corresponding to nucleotide
position 976 to 1227 of the CARD15 transcript
(NM_022162.1) was amplified from BAC clones. Clone
327F22 yielded a band of appropriate size.
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